Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGSWW) EBIT Margin (2020 - 2025)

GeneDx Holdings has reported EBIT Margin over the past 6 years, most recently at 11.77% for Q4 2025.

  • Quarterly results put EBIT Margin at 11.77% for Q4 2025, down 2097.0% from a year ago — trailing twelve months through Dec 2025 was 3.06% (up 454.0% YoY), and the annual figure for FY2025 was 3.06%, up 454.0%.
  • EBIT Margin for Q4 2025 was 11.77% at GeneDx Holdings, down from 2.78% in the prior quarter.
  • Over the last five years, EBIT Margin for WGSWW hit a ceiling of 9.21% in Q4 2024 and a floor of 529.56% in Q4 2022.
  • Median EBIT Margin over the past 5 years was 88.64% (2023), compared with a mean of 124.08%.
  • Biggest five-year swings in EBIT Margin: plummeted -35302bps in 2022 and later surged 48489bps in 2023.
  • GeneDx Holdings' EBIT Margin stood at 200.31% in 2021, then plummeted by -164bps to 529.56% in 2022, then soared by 92bps to 44.66% in 2023, then surged by 121bps to 9.21% in 2024, then plummeted by -228bps to 11.77% in 2025.
  • The last three reported values for EBIT Margin were 11.77% (Q4 2025), 2.78% (Q3 2025), and 8.73% (Q2 2025) per Business Quant data.